Table 3 Aminoglycoside therapy characteristics
From: An international survey on aminoglycoside practices in critically ill patients: the AMINO III study
|  | All (n = 931) | Amikacin (n = 614) | Gentamicin (n = 303) | Tobramycin (n = 14) |
|---|---|---|---|---|
Duration of therapy (days) | 2 [1; 3] | 2 [1; 3] | 2 [1; 3] | 2 [2; 4.75] |
Number of injections | 2 [1; 2] | 2 [1; 2] | 2 [1; 2] | 2 [1; 4] |
Second dose administered | 483 (52%) | 326 (53%) | 164 (53%) | 13 (93%) |
First dose in mg | – | 2000 [1500; 2250] | 440 [320; 560] | 500 [381; 555] |
First dose in mg per kg of TBW | – | 26 [21.9; 29.4] | 5.6 [4.3; 7.5] | 6 [5.1; 7.1] |
First dose in mg per kg of ABW | – | 267.8 [23.8; 29.4] | 6.2 [4.8; 7.8] | 6.1[5.4; 7.1] |
Infusion duration (min) | 30 [30; 30] | 30 [30; 30] | 30 [30; 30] | 30 [30; 30] |
Cmax after first dose | 437/931 (47%) | 341/614 (56%) | 90/303 (30%) | 6/14 (43%) |
Cmax value (mg L−1) | – | 73 [57; 90] | 21 [17; 25] | 19 [14; 26] |
Delay end of infusion and Cmax sampling (min) | 30 [30; 50] | 30 [30; 50] | 30 [30; 44] | 30 [26; 37] |
Targeted Cmax attainment after first dose | 295/437 (68%) | 241/341 (71%) | 53/90 (59%) | 1/6 (17%) |
Cmin after first dose | 501/880 (57%) | 347/577 (60%) | 145/289 (50%) | 6/14 (43%) |
Cmin above threshold | 353/498 (71%) | 230/347 (66%) | 118/145 (81%) | 5/6 (83%) |
Time from first dose to Cmin (h) | 22.9 [20.4; 24] | 22.6 [20.5; 24] | 23.4 [21.5; 24.1] | 24.4 [23.6; 26.1] |
Interval after first dose (h) | 26 [23; 43] | 26.7 [23; 45] | 24.8 [23; 34] | 24.5 [23; 29] |